Taurine is a crucial factor to preserve retinal ganglion cell survival

Advances in Experimental Medicine and Biology

Volumn 775, Issue , 2013, Pages 69-83

  Froger, Nicolas ^a,b   Jammoul, Firas ^a,b   Gaucher, David ^a,b   Cadetti, Lucia ^a,b   Lorach, Henri ^a,b   Degardin, Julie ^a,b   Pain, Dorothée ^a,b   Dubus, Elisabeth ^a,b   Forster, Valérie ^a,b   Ivkovic, Ivana ^a,b   Simonutti, Manuel ^a,b   Sahel, José Alain ^a,b,c,d,e,f   Picaud, Serge ^a,b,e  

^a INSTITUT DE LA VISION   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^f European Acad of Sci/Humanities   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TAURINE; TAURINE TRANSPORTER; VIGABATRIN; CARRIER PROTEIN; DRUG DERIVATIVE; GUANIDINOETHANESULFONIC ACID; MEMBRANE PROTEIN; NEUROPROTECTIVE AGENT;

ADULT; AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; GLAUCOMA; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA DEGENERATION; RETINA GANGLION CELL; RETINITIS PIGMENTOSA; TISSUE LEVEL; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; TIME;

ANIMALS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GLAUCOMA; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NEUROPROTECTIVE AGENTS; RATS; RETINAL GANGLION CELLS; RETINITIS PIGMENTOSA; TAURINE; TIME FACTORS; VIGABATRIN;

MLCS; MLOWN;

EID: 84878806443     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-6130-2_6     Document Type: Article

References (50)

1. Araie M, Crowston J, Iwase A, Tomidokoro A, Leung C, Zeitz O, Vingris A, Schmetterer L, Ritch R, Kook M, Erlich R, Gherghel D, Graham S, Pillunat L, Aung T, Hafez A, Liu J, Harris A (2009) Clinical relevance of ocular blood flow (OBF) measurements including effects of general medications or specific glaucoma treatment. Kugler Publications, Amsterdam, The Netherlands
2. Barres BA, Silverstein BE, Corey DP, Chun LL (1988) Immunological, morphological, and electrophysiological variation among retinal ganglion cells purified by panning. Neuron 1:791-803
3. Ben-Menachem E, Persson LI, Schechter PJ, Haegele KD, Huebert N, Hardenberg J, Dahlgren L, Mumford JP (1989) The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 27(Suppl 1):79S-85S
4. Brosnan JT, Brosnan ME (2006) The sulfur-containing amino acids: an overview. J Nutr 136:1636S-1640S
5. Buncic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, Logan WJ (2004) Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 111:1935-1942
6. Butler WH, Ford GP, Newberne JW (1987) A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol 15:143-148
7. Chen K, Zhang Q, Wang J, Liu F, Mi M, Xu H, Chen F, Zeng K (2009) Taurine protects transformed rat retinal ganglion cells from hypoxia-induced apoptosis by preventing mitochondrial dysfunction. Brain Res 1279:131-138
8. Curatolo P, Bombardieri R, Cerminara C (2006) Current management for epilepsy in tuberous sclerosis complex. Curr Opin Neurol 19:119-123
9. Duboc A, Hanoteau N, Simonutti M, Rudolf G, Nehlig A, Sahel JA, Picaud S (2004) Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann Neurol 55:695-705
10. El Idrissi A (2008) Taurine increases mitochondrial buffering of calcium: role in neuroprotection. Amino Acids 34:321-328
11. Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP, Stefansson E (2002) The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 21:359-393
12. Frisen L, Malmgren K (2003) Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81:466-473
13. Froger N, Cadetti L, Lorach H, Martins J, Bemelmans AP, Dubus E, Degardin J, Pain D, Forster V, Chicaud L, Ivkovic I, Simonutti M, Fouquet S, Jammoul F, Leveillard T, Benosman R, Sahel J-A, Picaud S (2012) Taurine provides neuroprotection against retinal ganglion cell degeneration. PLoS One 7(10):e42017
14. Garcia-Ayuso D, Salinas-Navarro M, Agudo M, Cuenca N, Pinilla I, Vidal-Sanz M, Villegas-Perez MP (2010) Retinal ganglion cell numbers and delayed retinal ganglion cell death in the P23H rat retina. Exp Eye Res 91:800-810
15. Gaucher D, Arnault E, Husson Z, Froger N, Dubus E, Gondouin P, Dherbecourt D, Degardin J, Simonutti M, Fouquet S, Benahmed MA, Elbayed K, Namer IJ, Massin P, Sahel JA, Picaud S (2012) Taurine deficiency damages retinal neurones: cone photoreceptors and retinal ganglion cells. Amino Acids 43:1979-1993
16. Hayes KC, Carey RE, Schmidt SY (1975) Retinal degeneration associated with taurine deficiency in the cat. Science 188:949-951
17. Heller-Stilb B, van Roeyen C, Rascher K, Hartwig HG, Huth A, Seeliger MW, Warskulat U, Haussinger D (2002) Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. FASEB J 16:231-233
18. Humayun MS, Prince M, de Juan E Jr, Barron Y, Moskowitz M, Klock IB, Milam AH (1999) Morphometric analysis of the extramacular retina from postmortem eyes with retinitis pigmentosa. Invest Ophthalmol Vis Sci 40:143-148
19. Imaki H, Moretz R, Wisniewski H, Neuringer M, Sturman J (1987) Retinal degeneration in 3-monthold rhesus monkey infants fed a taurine-free human infant formula. J Neurosci Res 18:602-614
20. Ito T, Kimura Y, Uozumi Y, Takai M, Muraoka S, Matsuda T, Ueki K, Yoshiyama M, Ikawa M, Okabe M, Schaffer SW, Fujio Y, Azuma J (2008) Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J Mol Cell Cardiol 44:927-937
21. Jammoul F, Degardin J, Pain D, Gondouin P, Simonutti M, Dubus E, Caplette R, Fouquet S, Craft CM, Sahel JA, Picaud S (2010) Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats. Mol Cell Neurosci 43:414-421
22. Jammoul F, Wang Q, Nabbout R, Coriat C, Duboc A, Simonutti M, Dubus E, Craft CM, Ye W, Collins SD, Dulac O, Chiron C, Sahel JA, Picaud S (2009) Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol 65:98-107
23. Kilic U, Kilic E, Jarve A, Guo Z, Spudich A, Bieber K, Barzena U, Bassetti CL, Marti HH, Hermann DM (2006) Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci 26:12439-12446
24. Kolomiets B, Sahel JA, Picaud S (2006) Single-unit activity and visual response characteristics in retinal ganglion cells of ex vivo retina recorded using 3D MEA microelectrode array recordings in mice. University College London, London
25. Kolomiets B, Dubus E, Simonutti M, Rosolen S, Sahel JA, Picaud S (2010) Late histological and functional changes in the P23H rat retina after photoreceptor loss. Neurobiol Dis 38:47-58
26. Krauss GL, Johnson MA, Miller NR (1998) Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 50:614-618
27. Leske MC (2009) Ocular perfusion pressure and glaucoma: clinical trial and epidemiologic findings. Curr Opin Ophthalmol 20:73-78
28. Macaione S, Ruggeri P, De Luca F, Tucci G (1974) Free amino acids in developing rat retina. J Neurochem 22:887-891
29. MacDonald ML, Rogers QR, Morris JG (1984) Nutrition of the domestic cat, a mammalian carnivore. Annu Rev Nutr 4:521-562
30. Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, Krauss GL (1999) Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 53:2082-2087
31. Mittag TW, Danias J, Pohorenec G, Yuan HM, Burakgazi E, Chalmers-Redman R, Podos SM, Tatton WG (2000) Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 41:3451-3459
32. Pasantes-Morales H, Quiroz H, Quesada O (2002) Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: a 3-year follow-up study. Metab Brain Dis 17:183-197
33. Pasantes-Morales H, Quesada O, Carabez A, Huxtable RJ (1983) Effects of the taurine transport antagonist, guanidinoethane sulfonate, and beta-alanine on the morphology of rat retina. J Neurosci Res 9:135-143
34. Pennesi ME, Nishikawa S, Matthes MT, Yasumura D, LaVail MM (2008) The relationship of photoreceptor degeneration to retinal vascular development and loss in mutant rhodopsin transgenic and RCS rats. Exp Eye Res 87:561-570
35. Quigley HA (1999) Neuronal death in glaucoma. Prog Retin Eye Res 18:39-57
36. Rascher K, Servos G, Berthold G, Hartwig HG, Warskulat U, Heller-Stilb B, Haussinger D (2004) Light deprivation slows but does not prevent the loss of photoreceptors in taurine transporter knockout mice. Vision Res 44:2091-2100
37. Ravindran J, Blumbergs P, Crompton J, Pietris G, Waddy H (2001) Visual field loss associated with vigabatrin: pathological correlations. J Neurol Neurosurg Psychiatry 70:787-789
38. Roska B, Werblin F (2001) Vertical interactions across ten parallel, stacked representations in the mammalian retina. Nature 410:583-587
39. Satsu H, Watanabe H, Arai S, Shimizu M (1997) Characterization and regulation of taurine transport in Caco-2, human intestinal cells. J Biochem 121:1082-1087
40. Schaffer SW, Azuma J, Mozaffari M (2009) Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol 87:91-99
41. Schmidt SY, Aguirre GD (1985) Reductions in taurine secondary to photoreceptor loss in Irish setters with rod-cone dysplasia. Invest Ophthalmol Vis Sci 26:679-683
42. Shareef SR, Garcia-Valenzuela E, Salierno A, Walsh J, Sharma SC (1995) Chronic ocular hypertension following episcleral venous occlusion in rats. Exp Eye Res 61:379-382
43. Tezel G (2006) Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res 25:490-513
44. Tomi M, Tajima A, Tachikawa M, Hosoya KI (2008) Function of taurine transporter (Slc6a6/TauT) as a GABA transporting protein and its relevance to GABA transport in rat retinal capillary endothelial cells. Biochim Biophys Acta 1778:2138-2142
45. van der Torren K, Graniewski-Wijnands HS, Polak BC (2002) Visual field and electrophysiological abnormalities due to vigabatrin. Doc Ophthalmol 104:181-188
46. Voaden MJ, Lake N, Marshall J, Morjaria B (1977) Studies on the distribution of taurine and other neuroactive amino acids in the retina. Exp Eye Res 25:249-257
47. Wang QP, Jammoul F, Duboc A, Gong J, Simonutti M, Dubus E, Craft CM, Ye W, Sahel JA, Picaud S (2008) Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina. Eur J Neurosci 27:2177-2187
48. Westall CA, Nobile R, Morong S, Buncic JR, Logan WJ, Panton CM (2003) Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol 107: 299-309
49. Wu JY, Prentice H (2010) Role of taurine in the central nervous system. J Biomed Sci 17(Suppl 1):S1
50. Yamori Y, Liu L, Mizushima S, Ikeda K, Nara Y (2006) Male cardiovascular mortality and dietary markers in 25 population samples of 16 countries. J Hypertens 24:1499-1505